ProCE Banner Activity

CE / CME

The Expanding Role of Pharmacists in Caring for Nonhospitalized Patients With COVID-19

Video

In this on-demand webcast, expert faculty discuss the pharmacists’ role in caring for nonhospitalized patients with COVID-19, COVID-19 treatment strategies, and management of individual patient scenarios.

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Pharmacists: 1.00 contact hour (0.1 CEUs)

Released: March 15, 2023

Expiration: March 14, 2024

No longer available for credit.

Share

Faculty

Julie Ann Justo

Julie Ann Justo, PharmD, MS, FIDSA, BCPS

Clinical Pharmacist Lead – Infectious Diseases
Inpatient Pharmacy
Dartmouth Hitchcock Medical Center
Lebanon, New Hampshire

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from

Pfizer, Inc.

Target Audience

This program is intended for physicians, pharmacists, and other HCPs involved in the management of nonhospitalized patients with current or previous COVID-19, including both specialists and primary care providers. This identified target audience will benefit from this education by gaining the knowledge and strategies necessary to individualize outpatient management of acute COVID and post-COVID conditions.

Program Learning Goal

To improve healthcare professionals’ (HCPs) competence in optimizing outpatient management of COVID-19, including timely diagnosis, risk stratification, and treatment, and to expand HCPs’ ability to apply emerging data on the epidemiology, presentation, and emerging data regarding prevention and management of post-COVID conditions.

Learning Objectives

After completing this activity, participants should be better able to:

  • Use best practices for risk stratification of nonhospitalized patients with COVID-19 to determine eligibility for outpatient treatment

  • Develop individualized care plans for outpatients diagnosed with SARS-CoV-2 infection based on guideline recommendations, current clinical data, and potential logistical or supply constraints

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Julie Ann Justo, PharmD, MS, FIDSA, BCPS: consultant/advisor/speaker: bioMérieux, Entasis Therapeutics, Gilead Sciences, Merck, Shionogi, Spero Therapeutics. 

The planners and content peer reviewers from Clinical Care Options, LLC do not have any relevant financial relationships to disclose. 

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.0 hour. To successfully complete this activity and receive credit, learners must follow these steps during the period from March 15, 2023, through March 14, 2024:

  1. Create an account or Login at https://clinicaloptions.com/
  2. Read the target audience, learning objectives, and faculty disclosures
  3. View and study the content in its entirety
  4. Submit answers to the post-test questions and evaluation questions online

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by clicking the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.

Format

This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Accreditation

Joint Accreditation Statement



In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Pharmacists

CCO designates this continuing education activity for?1.0 contact hour (0.10 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008176-0000-23-076-H01-P

Type of Activity:Application

Upon successfully completing the post-test with a score of 65% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Physician Continuing Medical Education
Credit Designation 
CCO designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit. Physicians should claim only the credit commensurate with the extent of their participation in the activity.